Copyright: ©Author(s) 2026.
World J Gastrointest Pharmacol Ther. Jun 5, 2026; 17(2): 118616
Published online Jun 5, 2026. doi: 10.4292/wjgpt.v17.i2.118616
Published online Jun 5, 2026. doi: 10.4292/wjgpt.v17.i2.118616
Figure 4 Stepwise therapeutic approach to prokinetic management.
Algorithm depicting the hierarchical management of motility disorders, beginning with dietary modification, followed by dopamine antagonists, selective 5-hydroxytryptamine type 4 receptor and motilin receptor agonists, and progressing to emerging experimental and clinical-trial therapies. 5-HT4: 5-Hydroxytryptamine type 4 receptor; FDA: Food and drug administration.
- Citation: Goyal O, Chowdhary R, Sehgal T, Joshi T, Bhambri A, Rampurawala IM, Sohi GS, Das A, Arora K, Vuthaluru AR, Goyal MK. Evolving prokinetic therapy: New targets and therapeutic opportunities in gastrointestinal motility disorders. World J Gastrointest Pharmacol Ther 2026; 17(2): 118616
- URL: https://www.wjgnet.com/2150-5349/full/v17/i2/118616.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v17.i2.118616